Chimerix Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
36,445.00
59,312.00
117,372.00
76,390.00
70,984.00
69,474
Depreciation, Depletion & Amortization
258.00
283.00
657.00
1,063.00
1,091.00
860
Other Funds
107,634.00
225,939.00
-
-
-
12,487
Funds from Operations
26,068.00
53,313.00
102,051.00
57,749.00
52,947.00
56,127
Changes in Working Capital
509.00
6,236.00
2,161.00
6,066.00
2,822.00
2,000
Net Operating Cash Flow
25,559.00
47,077.00
99,890.00
63,815.00
50,125.00
54,127
Capital Expenditures
193.00
1,018.00
2,211.00
841.00
151.00
Purchase/Sale of Investments
9,655.00
158,682.00
167,103.00
94,906.00
16,582.00
Net Investing Cash Flow
9,462.00
159,700.00
169,314.00
94,065.00
16,431.00
Issuance/Reduction of Debt, Net
4,950.00
5,700.00
4,688.00
-
-
Net Financing Cash Flow
106,167.00
225,263.00
161,347.00
608.00
779.00
Net Change in Cash
90,070.00
18,486.00
107,857.00
30,858.00
32,915.00
Free Cash Flow
25,752.00
48,095.00
102,101.00
64,656.00
50,276.00
Change in Capital Stock
3,483.00
5,024.00
166,035.00
608.00
779.00

About Chimerix

View Profile
Address
2505 Meridian Parkway
Durham North Carolina 27713
United States
Employees -
Website http://www.chimerix.com
Updated 07/08/2019
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R.